Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808

Published:2023-10 Issue:5 Volume:21 Page:546-554
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Carthon Bradley C.,Kim Se Eun,McDermott David F.^ORCID,Dutcher Janice P.,Puligandla Maneka,Manola Judith,Pins Michael,Carducci Michael A.^ORCID,Plimack Elizabeth R.,Appleman Leonard J.^ORCID,MacVicar Gary R.,Kohli Manish^ORCID,Kuzel Timothy M.^ORCID,DiPaola Robert S.,Haas Naomi B.^ORCID

Funder

National Institutes of Health

National Cancer Institute

ECOG-ACRIN Cancer Research Group

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference31 articles.

1. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma;Motzer;N Engl J Med,2018

2. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma;Choueiri;N Engl J Med,2021

3. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma;Motzer;N Engl J Med,2021

4. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma;Rini;N Engl J Med,2019

5. Cancer statistics, 2022;Siegel;CA Cancer J Clin,2022

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Special populations in metastatic renal cell carcinoma;Current Opinion in Oncology;2024-02-23

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP